Wanbangde

Wanbangde Pharmaceutical Holding Group Co., Ltd. (hereinafter referred to as the "Group") is primarily engaged in the pharmaceutical manufacturing and medical devices, focusing on the big health industry. It is a listed company on the Shenzhen Main Board in the pharmaceutical manufacturing sector (stock code: 002082), headquartered in Wenling, Taizhou, Zhejiang. It was previously ranked 341st among China's Top 500 Private Manufacturing Enterprises in 2020. The Group has two major industry sectors/divisions: 1. Pharmaceutical Industry: Wanbangde Pharmaceutical Group Co., Ltd. is a high-tech enterprise specializing in the R&D, production, and sales of modern traditional Chinese medicine, APIs, and formulations. It has production capabilities for 14 dosage forms including dropping pills, tablets, capsules, granules, oral solutions, small-volume injections, and large-volume injections, as well as chemical APIs and TCM extracts. It is one of the pharmaceutical enterprises in China with a relatively large number of drug dosage forms, currently holding 185 drug approval numbers. It has established a product portfolio characterized by natural plant-based drugs, with a focus on cardiovascular, cerebrovascular, and nervous system medications, while also developing respiratory, psychiatric, and digestive system drugs. The company has 66 product specifications included in the 2018 National Essential Medicines List, 113 in the 2023 National Medical Insurance Drug Catalog, and 13 in the Zhejiang Province Primary Healthcare Institutions List of Common Drugs Outside the Essential Medicines List (supplementary drugs). It also possesses globally advanced huperzine A raw materials and injections, as well as two core products with full intellectual property rights: Ginkgo Leaf Dropping Pills and TCM-protected varieties. The company consistently adheres to a technology-driven approach, with a well-established R&D system and a highly skilled R&D team capable of independent innovation. It has established R&D platforms such as the "China Pharmaceutical University - Wanbangde Modernization of Traditional Chinese Medicine Joint Research Center", "Zhejiang University - Wanbangde Modernization of Traditional Chinese Medicine Joint Research Center", "Provincial High-tech Enterprise R&D Center for Cardiovascular and Cerebrovascular Drugs", and "Model Academician Expert Workstation". It is recognized as a "National Torch Plan Key High-tech Enterprise". The company has received honors including "2022-2023 China Pharmaceutical Manufacturing Top 100", "2022-2023 China Pharmaceutical Industry Growth Top 50", "2022 Top 10 TCM Enterprises", "2021 China National Medicine Outstanding Brand Enterprise" (representative product: Ginkgo Leaf Dropping Pills), and "2021 China Pharmaceutical Industry Growth Top 50 Enterprises". 2. Medical Device Industry: Wanbangde Medical Technology Co., Ltd. was established in January 2016, covering an area of 137 mu with a building area of 130,000 square meters and a registered capital of 200 million yuan. As a subsidiary under the Group (stock code: 002082), it is a new international company specializing in high-end medical device R&D, equipment manufacturing, and hospital engineering services. Its main products include medical polymers, intelligent orthopedic products, modern protective supplies, and other medical device sectors. In recent years, the company has pursued an international development path of "going global and bringing in", introducing high-end medical device industrialization technology from South Africa to Wenling, Zhejiang, and establishing the provincial key project "Wanbangde - China-Africa Medical Science and Technology Park". In 2021, the park integrated intensive and intelligent production of domestic polymer medical products, benchmarked against international safety and epidemic prevention injection standards, and completed the construction of 10 fully automatic syringe production lines with a designed annual output of 1 billion syringes. It now owns six subsidiaries in South Africa and domestically, as well as three production and R&D bases in Wenling (Zhejiang), Yuhuan (Zhejiang), and Johannesburg (South Africa). The medical device sector holds 151 patents, including 27 invention patents and 61 utility model patents. Major honors: Zhejiang Province Harmonious Labor Relations Demonstration Enterprise, Zhejiang Province 2022 Happy Community Leader Enterprise, Zhejiang Province Industry-Education Integration Enterprise, Zhejiang Province University Graduate Internship Demonstration Base, Taizhou Municipal Advanced Employee Home, Taizhou Municipal Workers' Pioneer, Taizhou Municipal "Dual Integration and Dual Strengthening" Two-New Organization Party Building Demonstration Site, Demonstration Site for Collective Consultation on Capability-Based Wages, Wenling City Skill Recognition Self-Evaluation Unit (Levels 5, 4, 3, and 2), Wenling City "Five Goods" Clean Labor Union Demonstration Site, Wenling City "Three-Star" Non-Public Enterprise Reform Pilot Unit, Wenling City Safety and Health Cup Winning Unit. Employee benefits: 1. Working environment: sterile, constant temperature workshop with temperature around 25°C; 2. Accommodation: air-conditioned rooms, two people per room; 3. Meals: company cafeteria with meal subsidies; 4. Annual health check-ups, five social insurances paid per national standards, statutory holidays; 5. Rich paid vocational skills training with salary increases based on skill level; 6. Good promotion channels, capable individuals can advance to intermediate and senior technical and management positions.